Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Filing tables
Filing exhibits
DICE similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)
Registration Statement (Form S-3 No. 333-267702) and related prospectus of DICE Therapeutics, Inc., and
(2)
Registration Statements (Form S-8 Nos. 333-259565 and 333-263901) pertaining to the 2021 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan, of DICE Therapeutics, Inc.;
of our report dated March 15, 2023, with respect to the consolidated financial statements of DICE Therapeutics, Inc., included in this Annual Report (Form 10-K) of DICE Therapeutics, Inc., for the year ended December 31, 2022.
/s/ Ernst & Young LLP
San Jose, California
March 15, 2023